NCI is working to provide five to ten recommendations for Vice President Joe Biden’s cancer moonshot program, officials said at a recent advisory committee meeting.
At a meeting of the Frederick National Laboratory Advisory Committee May 11, top NCI officials described the mechanisms that will be used to provide recommendations for spending new money that may be directed at cancer research.
The institute’s Blue Ribbon Panel—consisting of 28 members representing academia, government, industry and patient advocates—has assembled seven working groups to focus on the following categories:
• Cancer immunology and prevention,
• Tumor evolution and progression,
• Precision prevention and early detection,
• Expanding clinical trials,
• Pediatric cancer,
• Enhanced data sharing, and
• Implementation sciences.
Each 10 to 12-member group is expected to provide two to three recommendations identifying scientific opportunities for acceleration.